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It has been more than 100 years since Paul Ehrlich reported that various water-soluble
dyes injected into the circulation did not enter the brain. Since Ehrlich’s first experiments,
only a small number of molecules, such as alcohol and caffeine have been found to cross
the blood-brain barrier, and this selective permeability remains the major roadblock to
treatment of many central nervous system diseases. At the same time, many central
nervous system diseases are associated with disruption of the blood-brain barrier that
can lead to changes in permeability, modulation of immune cell transport, and trafficking
of pathogens into the brain. Therefore, advances in our understanding of the structure
and function of the blood-brain barrier are key to developing effective treatments for a
wide range of central nervous system diseases. Over the past 10 years it has become
recognized that the blood-brain barrier is a complex, dynamic system that involves
biomechanical and biochemical signaling between the vascular system and the brain.
Here we reconstruct the structure, function, and transport properties of the blood-brain
barrier from an engineering perspective. New insight into the physics of the blood-brain
barrier could ultimately lead to clinical advances in the treatment of central nervous system
diseases.
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THE PHYSICS OF THE BLOOD-BRAIN BARRIER (BBB)
POWERING THE BRAIN
The BBB is the interface between the vascular system and the
brain, and hence we begin by reviewing the architecture of the
brain vasculature. The human brain is comprised of ∼100 bil-
lion neurons and consumes about 15–20W power. The metabolic
nutrients that supply the power are oxygen and glucose. The
brain, along with the liver and GI tract, are the most energy
expensive organs in the human body. Overall the brain accounts
for 15–20% of the base metabolic rate (BMR), consuming
15–20% of oxygen leaving the heart, and 15–20% of the glucose
consumed daily (Aiello andWheeler, 1995; Attwell and Laughlin,
2001; Fish and Lockwood, 2003; Lennie, 2003; Navarrete et al.,
2011). Since the brain does not have significant capacity to store
metabolic nutrients, fuel to power the brain is provided on-
demand by the lungs, and GI system which transfer oxygen and
glucose, respectively, to the vascular system. Therefore, the role
of the vascular system is crucial in delivering nutrients neces-
sary to maintain normal brain function. Interruption of cerebral
blood flow very quickly results in neuronal death; after cardiac
arrest apoptosis of neurons begins almost immediately, and brain
damage occurs after about 5min (Hossmann, 2006).
Most of the energy consumed by ATP hydrolysis in the brain
is used by neurons for generating nerve impulses (e.g., voltage-
and ligand-gated ion channels) and for maintaining ion gradi-
ents (e.g., sodium/potassium pumps; Attwell and Laughlin, 2001;
Shulman et al., 2004; Raichle and Mintun, 2006). The cerebral
metabolic rate (CMR) for ATP utilization in the human brain
is about 9.5μmol g−1 s−1 in gray matter and about 3μmol
g−1 s−1 in white matter (Zhu et al., 2012). Therefore, about
77% of the brain’s energy consumption is in cortical gray mat-
ter, which represents about 50% of the brain volume (Zhu et al.,
2012). The gray matter consists of neurons, dendrites, unmyeli-
nated axons, glial cells, and capillaries, whereas white matter is
mostly myelinated axons, glial cells, and capillaries. Due to the
increased energy demands, the capillary density is 2–4 times
higher in gray matter (Borowsky and Collins, 1989b; Heinzer
et al., 2008). Gray matter has a higher density of synapses and
higher levels of neural activity than white matter and hence
increased energy consumption is expected (Zhu et al., 2012). As
we show below, the architecture of the brain microvasculature is
dictated in large part by the energy needs of the neurons in the
brain.
BRAIN MICROVASCULATURE ACROSS SPECIES
The architecture of the brain microvasculature across species is
remarkably similar. The BMR of numerous species (both warm
blooded and cold-blooded organisms) follows Keliber’s law where
the BMR is proportional to body weight with an exponent of
0.75 (Kleiber, 1947). The oxygen (mL min−1) and glucose (μmol
min−1) CMRs increase with brain volume across species, with an
exponent of 5/6 (0.85), indicating that the brain is a major energy
consumer (Karbowski, 2007, 2009, 2011). The metabolic rate of
the human brain, normalized to its mass is about 11W kg−1,
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almost an order of magnitude larger than that of the human body
of 1.3W kg−1 (Aiello and Wheeler, 1995).
From the exponent of 5/6, it follows that the CMR normalized
by brain volume scales with brain volume (V) with an exponent
of −1/6 (CMR/V ∝ V−1/6; Karbowski, 2011). Cerebral blood
flow, normalized to brain volume, also has an exponent of −1/6
(CBF/V ∝ V−1/6; Karbowski, 2011), illustrating that cerebral
blood flow is directly proportional to CMR across species (CMR
∝ CBF). Indeed, studies in rat brains have shown a strong corre-
lation between local blood flow, glucose utilization, and capillary
density (Klein et al., 1986; Borowsky and Collins, 1989a).
The neuron density in the brain scales with brain volume with
an exponent of −1/6 (ρn ∝ V−1/6; Karbowski, 2011). The neg-
ative exponent reflects the difficulty in wiring and powering 3D
architectures with increasing brain size. The capillary length den-
sity also exhibits an exponent of −1/6 (ρc ∝ V−1/6) showing
that the number of neurons is proportional to the total length
of capillaries across species (Karbowski, 2011). Equivalently, the
capillary length density per neuron is constant across species.
The average capillary diameter is only weakly dependent on
brain volume with an exponent of 0.08 (dc ∝ V0.08), increasing
from about 4μm in the rat brain to about 7μm in the human
brain.
The fact that cerebral blood flow is directly proportional to
CMR and that the capillary length density per neuron is con-
stant across species provides evidence that the architecture of the
human brain microvasculature is not unique. Neural function
is constrained in part by energy demands and hence the spa-
tial distribution of capillaries is closely correlated with metabolic
function.
MICROVASCULATURE OF THE HUMAN BRAIN
The average adult human brain weighs about 1500 g and occupies
about 1200 cm3. The surface area of microvessels is 100–200 cm2
g−1 tissue (Crone, 1963; Gross et al., 1986), corresponding to
a total surface area of 15–25m2. In comparison, the surface
area of the gut is 300–400m2, the lung is about 100m2, and
the skin is about 2m2. The microvessel density is about 500m
cm−3 (Kreczmanski et al., 2005, 2009), corresponding to a total
microvessel length of about 600 km in the adult human brain
(Zlokovic, 2005).
The human brain is comprised of about 100 billion neu-
rons and a similar number of glial cells. Neurons, astrocytes,
microglia, and pericytes account for almost 80% of the brain
volume. The extracellular space occupies 15–30%of the brain vol-
ume (Nicholson, 2001) and the brain vasculature about 3% of
the brain volume.(Nicholson, 2001) Capillaries in the brain may
be as small as 7–10μm in diameter and the average intercapil-
lary distance is about 40μm (Duvernoy et al., 1983; Nicholson,
2001). Consequently, the cell body of a neuron is typically about
10–20μm from the nearest capillary (Schlageter et al., 1999).
Blood is supplied to the brain through four arteries, the inter-
nal carotid arteries and the vertebral arteries, which merge in
the circle of Willis at the base of the brain (Hossmann, 2006).
Each carotid artery supplies about 40% of the total blood flow
to the brain. The flow rate to the brain is about 800mL min−1
(Zlokovic, 2005), about 15–20% of the total blood flow from
the heart. From the circle of Willis, intercerebral arteries, and
pial arteries are distributed along the surface of the brain, from
which arteries and arterioles penetrate into the brain parenchyma
perpendicular to the brain surface, leading to the network of
capillaries. In the human brain, capillaries form numerous con-
nections before merging into venules and veins. Blood flow
exits the brain through the jugular veins. While the arteries
and arterioles are sheathed in one or more layers of smooth
muscle cells, the capillaries are surrounded by pericytes and
astrocytes.
The architecture of the vasculature can be described in terms
of individual capillary segments between two junctions. The
capillary length density ρc = NcLc/V where Nc is the num-
ber of segments of average length Lc . Typical segment lengths
in a mouse cortex are about 60μm, with segment densi-
ties and junction densities of about 10,000mm−3 (Heinzer
et al., 2008). The tortuosity (τ) of a segment is given by τ =
λ/c, where λ is the length of a segment and c is the chord
length. Typical values for tortuosity in the mouse cortex are
1.2–1.3 (Heinzer et al., 2008). The number of segments con-
nected at a junction n ≈ 3.5, indicating that a significant frac-
tion of junctions are higher order than a simple bifurcation
(n = 3).
Blood flow and heart rate are regulated by the autonomic ner-
vous system, located in the medulla in the lower midbrain. The
medulla receives sensory input from other brain regions and stim-
ulates cardiovascular responses through nerve fibers that travel
to the heart and blood vessels. Varicosities along the fibers are
the sites for release of neurotransmitters. Autonomic and sensory
nerve fibers are associated with the cerebral arteries, pial arteries,
and arterioles in the brain, and release neurotransmitters such
as norepinephrine (NE) and neuropeptide Y (NPY) that result
in vessel constriction, and acetylcholine (Ach) and vasoactive
intestinal polypeptide (VIP) that can dilate vessels. Regulation
of brain capillaries by the autonomic nervous system has not
been established, however, pericytes can dilate and contract in
response to different neurotransmitters suggesting the possibil-
ity of autonomous signaling (Peppiatt et al., 2006; Fisher, 2009;
Fernandez-Klett et al., 2010; Krueger and Bechmann, 2010).
Over the last 3 million years, from Australopithecus to Homo
sapiens, the size of the human brain has increased from about
400 cm3 to about 1200 cm3 in modern humans (Aiello and
Dunbar, 1993; Potts, 2011). This increase has not been continu-
ous but has had several periods of rapid expansion. The expensive
tissue hypothesis postulates that the increase in power consump-
tion associated with increasing brain size must be balanced by
a decrease in the power requirements in the liver and GI tract
(Aiello and Wheeler, 1995). However, recent evidence suggests
that these evolutionary increases in brain size are related to an
increase in energy input, such as improved diet and availabil-
ity of food, and changes in energy allocation, such as decreased
energy costs associated with locomotion (Holliday, 1986; Roth
andDicke, 2005; Navarrete et al., 2011). During prenatal and early
childhood development, the developing brain consumes 60% or
more of the basal metabolism, and it has been argued that this is a
fundamental limitation to brain size in humans (Snodgrass et al.,
2009).
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The microvasculature in the brain differs from other capillary
networks in the human body, for example those in the lung, in
two significant ways. First, the brainmicrovasculature tightly reg-
ulates transport into the brain. Second, the capillaries can exhibit
significant plasticity in response to abnormal physiological con-
ditions. For example, during ischemia capillaries can dilate to
increase oxygen influx (Boero et al., 1999; Ito et al., 2003; Hauck
et al., 2004).
The architecture of the brain microvasculature is very similar
across species, indicating that the human brain microvascula-
ture is not physically unique. However, an important question is
whether the human blood-brain barrier is functionally different
from other species. Evidence suggests that there may be signifi-
cant biochemical differences, for example in the expression levels
of transporters and pumps thatmake the human blood-brain bar-
rier unique (Hammarlund-Udenaes et al., 2008). However, the
evolutionary pressures that influenced these differences remains
to be established. Elucidating these differences is key in studies of
central nervous system diseases and in developing drug therapies.
MAINTAINING BRAIN HOMEOSTASIS
The supply of metabolic nutrients to the human brain is achieved
through a network of over 600 km of small capillaries, about
7μm in diameter, such that each neuron is within 20μm of
a capillary. The drawback of this architecture is that the brain
requires a tightly regulated local environment for cells to func-
tion. Since the brain microvasculature has a very large surface
area (15–25m2), maintaining homeostasis and preventing inter-
ference with signal generation and transmission in is a major
challenge.
The blood-brain barrier is responsible for maintaining home-
ostasis of the brain by regulating the chemical environment,
immune cell transport, and the entry of xenobiotics (Hawkins
and Davis, 2005; Abbott et al., 2010). The concentrations of water,
ions, amino acids, hormones, and neurotransmitters in the blood
undergo fluctuations, particularly after eating or exercise. If such
fluctuations were allowed to occur in the brain it would lead to
local disruption of signal propagation and uncontrolled neural
activity, and hence transport from the capillary lumen to the brain
parenchyma must be tightly regulated. Immune cell transport
(e.g., leukocytes) must also be regulated as the brain is contained
in a fixed volume in the skull and an inflammatory response could
lead to an increase in intercranial pressure or cerebral edema.
Finally, the entry of toxins and pathogens, such as bacteria and
viruses circulating in the blood, can lead to neuron cell death
and hence must also be prevented (Begley and Brightman, 2003;
Hawkins and Davis, 2005; Abbott et al., 2010).
The tight junctions formed by brainmicrovascular endothelial
cells (BMECs) regulate paracellular transport whereas transcellu-
lar transport is regulated by specialized transporters, pumps, and
receptors (Figure 1) (Chishty et al., 2001; Demeule et al., 2002;
Hawkins et al., 2002; Ohtsuki and Terasaki, 2007; Ueno, 2009;
Abbott et al., 2010; Hartz and Bauer, 2011).
CIRCUMVENTRICULAR ORGANS
While the blood-brain barrier maintains homeostasis, there are
specialized regions of the brain that allow direct communication
FIGURE 1 | The blood-brain barrier. (A) Schematic illustration of transport
across the brain microvascular endothelial cells (BMECs) that form the
lumen of brain capillaries. Paracellular transport is severely restricted due to
the formation of tight junctions between endothelial cells. Metabolic
nutrients and other essential molecules are transported across the luminal
and abluminal membranes by channels, pumps, or mediated transport
systems. Small lipophilic molecules can passively diffuse across the lipid
bilayer but, in many cases, are returned to the blood by efflux pumps. (B)
Proposed molecular interactions at tight junctions. Lateral association of
claudins (cis-interaction) results in the formation of oligomers whereas
association of claudins on opposing membranes (trans-interaction) results
in tight junction formation. Multiple regions of trans-interactions appear as
particles in electron microscopy images.
between the brain and the vascular system. In the circumven-
tricular organs, located at the surface of the third and fourth
ventricles, the blood-brain barrier is more permeable. Neurons
and glial cells at these sites can sense changes in the concen-
tration of various molecules, such as hormones, and secrete
hormones, neurotransmitters, or cytokines into the circulation
(Ganong, 2000; Duvernoy and Risold, 2007; Benarroch, 2011).
These organs include: the neurohypophysis (posterior pituitary),
the median eminence, the area postrema (vomiting center),
the subfornical organ, and the vascular organ of the lamina
terminalis.
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HISTORY
In 1885, Paul Ehrlich reported that various water-soluble dyes
injected into the circulatory system did not stain the brain and
spinal cord, and hypothesized that the CNS had a lower affin-
ity for these dyes (Ribatti et al., 2006; Liddelow, 2011). In 1898,
Biedl and Kraus showed that cholic acids (bile acids) that induce
seizures and coma when injected into the brain, were not toxic
when injected into the circulatory system (Ribatti et al., 2006). In
1900, Lewandowsky reported similar findings with potassium fer-
rocyanide and also concluded that there was limited permeation
from the circulatory system into the brain (Ribatti et al., 2006),
a phenomenon to which he ascribed the term bluthirnschranke
(blood-brain barrier). Later, Ehrlich’s student Edwin Goldmann
showed that the water-soluble dye trypan blue (MW = 960.8)
injected into cerebrospinal fluid readily stained central nervous
tissue blue, contradicting Ehrlich’s conclusion of a lower binding
affinity of the central nervous system for these dyes, and sup-
porting the hypothesis of limited permeation from the circulatory
system into the brain (Ribatti et al., 2006). In 1967, Reese and
Karnovsky used high resolution electron microscopy to demon-
strate that horseradish peroxidase (HRP, 40 kDa) was prevented
from entering the CNS by tight junctions (Bradbury, 1993). They
showed that the tight junctions were continuous and concluded




Historically, the blood-brain barrier has been defined by the
layer of endothelial cells that form the vessel/capillary walls.
More recently, the concept of the neurovascular unit has been
introduced to recognize that brain health depends on functional
interactions between neurons and non-neuronal cells such as
vascular cells (endothelial cells and pericytes) and glia (astro-
cytes, microglia, and oligodendroglia; Figure 2) (Hawkins and
Davis, 2005; Abbott et al., 2010). This is a highly dynamic system
in which cells transduce biochemical and biomechanical signals
in complex microenvironments involving basement membrane
and extracellular matrix. These non-neuronal cells are respon-
sible for the physical, biochemical, and immune barriers of the
CNS that regulate the microenvironment of the neurons which
is key for signal transduction, remodeling, angiogenesis, and
neurogenesis.
ENDOTHELIAL CELLS
The endothelial cells that line the microvasculature in the brain
define the interface between the vascular system and the brain.
These cells function as adaptive non-linear input/output devices
where input from biomechanical and biochemical forces in the
local microenvironment of the neurovascular unit influences cell
phenotype as manifested by cell morphology, protein expression,
gene expression, proliferation, transport, etc. (Dejana, 2004; Aird,
2005, 2007). In addition to biochemical and biomechanical input
from the vascular system, numerous paracrine signaling pathways
between microvascular endothelial cells and astrocytes and peri-
cytes are responsible for maintenance of the blood-brain barrier
(Aird, 2007; Abbott et al., 2010).
FIGURE 2 | The neurovascular unit. The microvascular endothelial cells
that form the lumen of brain capillaries are partially covered by pericytes
and basement membrane, and almost completely surrounded by the end
feet of astrocytes. Functional interactions between BMECs, astrocytes,
pericytes, other glial cells, and neurons are key to regulating brain
homeostasis. Blood flow is associated both biomechanical and biochemical
signaling mediated by multiple cell types and soluble factors. The brain
microvascular endothelial cells function in a cylindrical geometry with high
curvature and experience shear stress resulting from blood flow. The
BMECs and pericytes are surrounded by basement membrane consisting
primarily of fibronectin, laminin 1, and collagen type IV. The extra-cellular
matrix in the brain is based on hyaluronic acid.
In the brain microvasculature, cell-cell junctions are key to
maintaining the integrity of the brain microvasculature and
regulating paracellular transport. Cell-cell adhesion is achieved
through the formation of adherens junctions and tight junc-
tions (Bazzoni and Dejana, 2004; Dejana, 2004; Aird, 2007). Both
adherens junctions and tight junctions involve homophilic inter-
actions between the extracellular domains of membrane proteins
and are linked to the actin cytoskeleton via intracellular partners.
Endothelial adherens junctions are formed by the extracellular
domains of vascular endothelial cadherin (VE-cadherin) and are
linked to the actin cytoskeleton inside the cell via proteins such
as α-catenin, β-catenin, and vinculin (Bazzoni and Dejana, 2004;
Dejana, 2004).
The tight junctions in the brain microvasculature prevent
paracellular transport of most molecules and severely restrict
transport of small ions. Therefore, transcellular transport is
responsible for most molecular trafficking between the vascular
system and the brain. Various methods for transient disruption
of tight junctions have been explored for drug delivery, and local
disruption of tight junctions is associated with many diseases of
the central nervous system.
Tight junctions are formed between claudins (Nitta et al.,
2003), although other proteins such as occludin are also present
(Hawkins and Davis, 2005; Furuse and Tsukita, 2006). These tight
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junction membrane proteins are connected to the actin cytoskele-
ton via zona occludin (ZO) adaptor molecules (ZO-1 and ZO-2;
Hawkins and Davis, 2005). The claudin family consists of more
than 20 proteins that are essential for the formation of tight junc-
tions. Claudin-5 is the isoform most commonly found in the
BBB (Morita et al., 1999; Nitta et al., 2003; Hewitt et al., 2006),
although claudin-1 and claudin-12 are also associated with tight
junction formation (Wolburg and Lippoldt, 2002; Dejana, 2004;
Abbott et al., 2006). Antibodies to claudin-5, occludin, and ZO-
1 are commonly used as markers of tight junction formation in
monolayers of BMECs (Cecchelli et al., 2007). Adherens junctions
and tight junctions are structurally and functionally linked. For
example, evidence suggests that VE-cadherin at adherens junc-
tions upregulates the gene encoding the tight junction protein
claudin-5 (Dejana, 2004; Taddei et al., 2008).
In high resolution electron microscope images, tight junctions
appear as a series of discrete sites of apparent fusion near the api-
cal surface (Reese and Karnovsky, 1967; Brightman, 1977). These
sites are often described as strands of “particles” along the junc-
tion (Figure 2) (Tsukita and Furuse, 1999; Tsukita et al., 2001);
the backbone of these strands is composed of claudins.
The claudins have a molecular weight of about 23 kDa and
have four transmembrane segments, one intracellular loop, N-
and C-terminal cytoplasmic domains, and two extra cellular loops
(Furuse and Tsukita, 2006; Krause et al., 2009). The first extracel-
lular loop ECL1 consists of about 50 amino acids whereas ECL2
consists of about 25 amino acids (Krause et al., 2009). Both of the
extra-cellular loops (ECL1 and ECL2) of claudin-5 are thought
to play a role in tight junction formation (Krause et al., 2009).
Claudin-5 forms oligomers in one membrane via cis-interactions
between ECL2s (Piontek et al., 2008). Trans-interactions between
ECL2s on opposing membranes result in polymerization and for-
mation of the particles observed in electron microscopy.(Piontek
et al., 2008) Mutations of the two cysteines in claudin-5 have
been shown to reduce barrier properties, suggesting that these two
residues are important in tight junction formation (Wen et al.,
2004).
The morphology of microvascular endothelial cells is depen-
dent in part on biomechanical input from the vascular system.
The shear stress associated with blood flow results in elonga-
tion and alignment of endothelial cells in the direction of flow
(Caplan et al., 1974; Nerem et al., 1981; Ohashi and Sato, 2005;
Aird, 2007). In vitro studies have confirmed that the elongation
and alignment of endothelial cells in a 2D confluent monolayer
increases with increasing shear stress (Levesque and Nerem, 1985;
Malek and Izumo, 1996). In large vessels, there are many cells
around the perimeter, however, in small capillaries endothelial
cells can wrap around to form tight junctions with themselves, as
well as their neighbors (Nag, 2003). Shear stress can also upreg-
ulate genes associated with junctional proteins and transporters
(Cucullo et al., 2011).
The turnover of BMECs, measured as the mitotic index or the
turnover time, is thought to be very low (Hobson and Denekamp,
1984; Ekstrand et al., 2008). However, most studies are based
on extrapolation from relatively short intervals. The activation
and increase in turnover of BMECs due to angiogenesis and vas-
cular remodeling is also unknown. Similarly, the response of a
capillary to endothelial cell apoptosis or disruption is not well-
understood. Endothelial progenitor cells from bone marrow may
be involved in repair of the blood-brain barrier however, the sig-
naling processes involved in recruiting these cells and initiating
differentiation are not known (Asahara et al., 2011).
ASTROCYTES
Astrocytes are involved in multiple processes in the brain, includ-
ing regulation of ion and water concentration, the clearance of
neurotransmitters, proliferation of stem cells, control of the num-
ber of synapses, and maintenance of the BBB (Ullian et al., 2001;
Lee et al., 2003; Volterra and Meldolesi, 2005; Abbott et al.,
2006; Fiacco et al., 2009; Freeman, 2010; Halassa and Haydon,
2010). Morphologically, astrocytes are usually star shaped with
many processes or protrusions emanating from the cell body,
with an overall diameter of about 140μm in the human brain
(Oberheim et al., 2009). Astrocytes interact with microvascu-
lar endothelial cells through the end-feet of the protrusions that
wrap around the capillary (Abbott, 2002; Abbott et al., 2006).
Brain capillaries are often almost completely surrounded by astro-
cytic end-feet and one astrocyte may contact multiple capillaries
(Oberheim et al., 2009). Astrocytes form contacts with microves-
sels and the synapses between neurons, and play an important
role in matching oxygen and glucose transport to neural activ-
ity through regulation of local blood flow (Zonta et al., 2003;
Iadecola, 2004; Takano et al., 2006; Iadecola and Nedergaard,
2007). Evidence suggests that intracellular Ca2+ is involved in
blood flow regulation since neuronal stimulation results in an ele-
vation of intracellular Ca2+ concentration in astrocyte end-feet
(Iadecola, 2004).
Astrocytes participate in the formation of the BBB by enhanc-
ing tight junction formation, modulating the expression and
polarization of transporters, and promoting specialized enzyme
systems (debault and Cancilla, 1980; Janzer and Raff, 1987;
Abbott, 2002; Lee et al., 2003; Haseloff et al., 2005; Abbott
et al., 2006). Several astrocyte derived factors, including glial-
derived neurotrophic factor (GDNF), basic fibroblast growth
factor (BFGF), and angiopoetin-1 (ANG-1) are known to induce
blood-brain barrier characteristics in endothelial cells (Haseloff
et al., 2005; Abbott et al., 2006).
PERICYTES
Pericytes wrap around microvessels and capillaries in the brain
(Sims, 1986; Fisher, 2009; Attwell et al., 2010; Krueger and
Bechmann, 2010; Dalkara et al., 2011; Winkler et al., 2011) and
communicate with endothelial cells, astrocytes, and neurons in
the neurovascular unit (Bonkowski et al., 2011). Morphologically,
pericytes tend to be aligned with the vessel axis and extend
protrusions that wrap around the capillaries (Bonkowski et al.,
2011). A thin layer of basement membrane separates pericytes
from endothelial cells, and from surrounding astrocyte end-feet.
The ratio of pericytes to endothelial cells is typically around 1:3
(Shepro and Morel, 1993). Direct peg-and-socket contacts that
span the intervening basement membrane and gap junctions with
endothelial cells initiate multiple signaling pathways (Bonkowski
et al., 2011). For example, platelet-derived growth factor B
(PDGF-B) on endothelial cells binds with the corresponding
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receptor (PDGFR-B) on pericytes, regulating recruitment of
pericytes as well as their proliferation (Bell et al., 2010; Dalkara
et al., 2011; Winkler et al., 2011).
Pericytes are contractile, with actin stress fibers throughout
the cell body, and contribute to the regulation of blood flow by
controlling capillary diameter (Peppiatt et al., 2006; Hamilton
et al., 2010; Dalkara et al., 2011). In cell culture, pericytes
are usually identified by α-smooth muscle actin, which is not
expressed in endothelial cells, although expression can be het-
erogeneous.(Dalkara et al., 2011) Pericytes do not express GFAP,
expressed by astrocytes, or vWF, expressed by ECs.
Studies in mice have shown that perictyes are recruited to
nascent capillaries during development (Daneman et al., 2009,
2010) and are key for development of the BBB and regulating
transport across the BBB (Armulik et al., 2005, 2010; Daneman
et al., 2009, 2010; Kim et al., 2009) Indeed, pericyte loss leads
to locally reduced cerebral blood flow and breakdown of the
blood-brain barrier (Armulik et al., 2010; Bell et al., 2010).
Pericytes are able to either enhance or impair blood brain
barrier function in in vitro models depending on their state
of differentiation. Pericytes differentiated with TGFβ are α-
actin positive and have been found to decrease transendothelial
electrical resistance (TEER), while pericytes differentiated with
BFGF are α-actin negative and increase TEER above controls
(Thanabalasundaram et al., 2011).
CELL LINES FOR RESEARCH
A major challenge for the development of in vitro models of
the BBB is the availability of appropriate cell lines, particularly
BMECs. An in vitro model of the human BBB should exhibit
restricted paracellular transport (TEER = 1 kcm2, Psucrose <
10−7 cm s−1), BMECs with the morphology and characteris-
tics typical of the BBB, expression of BBB-specific markers and
transporters, and be readily available, convenient to use, and
reproducible (Reichel et al., 2003). While primary human BMECs
are often considered preferable for in vitromodels, the difficulties
in harvesting and purification of these cells can significantly limit
accessibility and reliability (Stins et al., 1997; Bernas et al., 2010).
In general, primary cells are used only at very low passage num-
bers to avoid down-regulation of BBB characteristics (Reichel
et al., 2003). In contrast, currently available cell lines can over-
come limitations associated with accessibility and convenience,
but do not exhibit all of the required features of the human
BBB (Sloan et al., 2012). Nevertheless, specific cell lines may
recapitulate properties that are necessary for some physiological,
pathological, or pharmacological applications. Common sources
for animal BMECs include rodent, bovine, and porcine brain cor-
tices. Primary astrocytes and pericytes can also be extracted from
the brain cortex (Siddharthan et al., 2007). Advances in stem cell
engineering suggest that differentiation of stem cells to BMECs
(Lippmann et al., 2012) and astrocytes (Krencik et al., 2011) may
ultimately solve the problem of limited cell lines.
BASAL LAMINA AND ECM
The basement membrane surrounding the endothelial cells and
pericytes is comprised of fibronectin, laminin (411, 421, and
511) (Aumailley et al., 2005), and collagen type IV (Tilling et al.,
1998, 2002; Hartmann et al., 2007). The thickness of the base-
ment membrane, determined from electron microscope images,
is about 100 nm (Nag, 2003). Endothelial cell monolayers on
fibronectin, laminin 1, and collagen type IV show enhanced
TEER, suggesting a role for the basement membrane in enhanc-
ing the formation of tight junctions (Tilling et al., 1998, 2002;
Hartmann et al., 2007).
The extracellular matrix in the brain is composed of four
main components: hyaluronic acid (HA), lecticans, hyaluro-
nan and proteoglycan link proteins (HAPLNs), and tenascins
(Zimmermann and Dours-Zimmermann, 2008). Common ECM
proteins such as fibronectin and collagen type I are not present
in the brain (Sanes, 1989). HA is a long unbranched polysac-
charide with negatively charged disaccharide repeat units, and is
unique amongst the glycosaminoglycans (GAGs) in that it is non-
sulfated (Laurent and Fraser, 1992; Toole, 2004; Zimmermann
and Dours-Zimmermann, 2008; Ananthanarayanan et al., 2011).
HA is synthesized by hyaluronan synthases at the inner surface of
the plasmamembrane, and can have amolecular weight as high as
107 Da (Zimmermann and Dours-Zimmermann, 2008). HA can
interact with cells through binding to cell surface receptors, such
as CD44 and RHAMM (Turley et al., 2002). The lecticans are a
family of chondroitin sulfate proteoglycans with an HA binding
domain and include aggrecan, versican, neurocan, and brevi-
can (Yamaguchi, 2000). The tenascins (Tns) are large multimeric
glycoproteins. Tn-C andTn-R are thought to bind tomultiple lec-
ticans and link proteins thereby crosslinking the HA and forming
a 3D network (Zimmermann and Dours-Zimmermann, 2008).
The interstitial fluid in the brain is similar in composition to
blood plasma, however, it has lower K+ and Ca2+ concentrations
but higher Mg2+ concentration. In addition, the interstitial fluid
has a lower protein content than plasma.
EXTRACELLULAR SPACE (ECS)
The ECS is the region between cells in the brain and provides
the main pathway for transport between capillaries and neurons
and other cells in the brain. Although most neurons are within
10–20μm of a capillary, transport in the extracellular space is
usually much faster than transport across the BBB and hence
is particularly important for local penetration of a solute. The
ECS consists of the hyaluronan-based ECM and a fluid phase,
and is characterized by a volume fraction α (= VECS/Vbrain) of
0.15–0.30 (Sykova and Nicholson, 2008). The fluid phase serves
as a reservoir for extracellular ions necessary for generating action
potentials, a medium for transporting molecules such as neuro-
transmitters involved in signaling, and for transporting essential
molecules between microvessels and cells in the brain. The extra-
cellular volume fluctuates during normal brain function and
decreases during development and aging (Sykova and Nicholson,
2008; Kroeger et al., 2010).
The geometry of the extracellular space has beenmodeled as an
interconnected network of sub-100 nm pores resembling sheets
and tunnels (Sykova and Nicholson, 2008; Kinney et al., 2013).
Sheets represent regions where the plasmamembranes of two cells
are in close proximity, similar to two parallel plates, and tunnels
correspond to approximately cylindrical channels. The geometry
of the network of pores in the ECS restricts diffusion in the brain
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compared to free diffusion, and is characterized by the tortuosity,
λ which is defined by the ratio (free/brain)
1/2 whereDfree is the
diffusion coefficient in solution and Dbrain is the diffusion coef-
ficient in the brain (Nicholson, 2001). The tortuosity takes into
account the fact that molecules must detour around cells during
transport.
Results from tracer experiments suggest a value of λ ≈ 1.6
in the rat brain. Since the diffusion coefficient for K+ and Cl−
ions in aqueous solution is around 2× 10−5 cm2 s−1, a tor-
tuosity of 1.6 implies a diffusion coefficient in the brain of
around 0.8 × 10−5 cm2 s−1. Analysis of in vivo experiments using
probes with different hydrodynamic radii suggests effective pore
dimensions of about 40 nm between parallel plates and about
60 nm for cylindrical channels (Thorne et al., 2005; Thorne and
Nicholson, 2006). As a result, the transport of molecules or par-
ticles approaching these dimensions will be limited due to steric
hindrance and drag by the pore walls (Thorne et al., 2005; Thorne
and Nicholson, 2006).
While global biophysical parameters such as ECS volume frac-
tion, tortuosity, and effective pore size have been estimated, the
details of the physico-chemical properties that control transport
between capillaries and neurons and other cells in the brain
remain to be established. Transport in the ECS may also be
modulated by dead-end branches in the ECS network, transient
binding with the ECM in the extracellular space, transient bind-
ing with cell membranes, or cell uptake (Sykova and Nicholson,
2008).
SHEAR STRESS
Blood pressure exerts a force normal to a vessel wall that imposes
a circumferential stress on the vessel, whereas blood flow results
in a frictional drag, or shear stress, parallel to the endothelium
in the direction of blood flow. These stresses play an important
role in regulating endothelial cell morphology and function, and
in mediating a wide range of signaling and transport processes
between the vascular system and surrounding tissue (Chien,
2007; Hahn and Schwartz, 2009; Johnson et al., 2011; Conway
and Schwartz, 2012). These stresses are also thought to play an
important role in regulation of the blood-brain barrier (Krizanac-
Bengez et al., 2004; Neuwelt et al., 2008, 2011; Tarbell, 2010;
Cucullo et al., 2011).
For an ideal Newtonian fluid (incompressible), the shear stress
τ in a straight cylindrical vessel under constant laminar flow is
given by the Poiseuille equation: τ = 4μQ/πr3 where μ is the
dynamic viscosity,Q is the volumetric flow rate, and r is the radius
of the lumen. Therefore, the magnitude of the shear stress on
the endothelium is proportional to the flow rate and viscosity,
and inversely proportional to r3. Consequently, endothelial cells
in vessels with high flow rate and small diameter are exposed to
large shear stress.
The viscosity of blood is about 4 cP (0.004 Pa·s), signifi-
cantly larger than the viscosity of water of 0.7 cP (0.0007 Pa·s) at
37◦C, primarily due to the presence of red blood cells. Typical
time averaged values of shear stress are 4–30 dynes cm−2 in
the arterial circulation and 1–4 dynes cm−2 in the venous cir-
culation (Turitto, 1982; Kamiya et al., 1984; Papaioannou and
Stefanadis, 2005; Koutsiaris et al., 2007; Dolan et al., 2013).
The flow rate in capillaries is typically from 6 to 12 nL min−1
corresponding to a shear stress of 10–20 dynes cm−2 for a
capillary 10μm in diameter (taking μ = 1 cP or 0.001 Pa s;
Kamiya et al., 1984).
As described above, the viscosity of bulk blood is around 4
cP, significantly higher than the viscosity of water, due in large
part to the density of red blood cells. A complication arises in
small capillaries since cells tend to avoid the vessel walls result-
ing in a cell-free layer within about 3μm of the surface that has
a viscosity close to that of water, a phenomenon known as the
Fahraeus—Lindqvist effect (Fahraeus and Lindqvist, 1931). For
large diameter vessels, this effect is negligible and the effective vis-
cosity is close to the bulk viscosity of blood. However, for smaller
diameter vessels, the cell-free layer can become a significant frac-
tion of the cross-sectional area resulting in a decrease in effective
viscosity.
TRANSPORT ACROSS THE BBB
INTRODUCTION
The barrier function of the BBB is critical for regulating transport
to the brain, but also represents a significant roadblock in deliv-
ering drugs to the brain (Pardridge, 2003, 2005, 2006, 2008, 2010;
Hawkins and Davis, 2005; Ohtsuki and Terasaki, 2007). Only very
few CNS disorders, such as depression, schizophrenia, chronic
pain, and epilepsy, are currently treatable with small molecule
drug therapy. The BBB is the major roadblock in developing
therapies for CNS diseases including neurodegenerative diseases,
cerebrovascular diseases, and brain cancer. Therefore, methods
to study the transport of drugs and other molecules across the
blood-brain barrier are key to understanding how the BBB regu-
lates transport and will be invaluable for drug discovery and the
treatment of CNS diseases (Cecchelli et al., 2007; Kuhnline Sloan
et al., 2012).
The formation of tight junctions effectively eliminates paracel-
lular transport across the blood-brain barrier (de Boer et al., 2003;
Cecchelli et al., 2007; Abbott et al., 2010; Giacomini et al., 2010).
Transcellular transport can occur through various mechanisms
(Lee et al., 2001; de Boer et al., 2003; Cecchelli et al., 2007; Ohtsuki
and Terasaki, 2007; Ueno, 2009; Abbott et al., 2010; Giacomini
et al., 2010), as illustrated in Figure 3. Small lipophilic molecules
can enter the brain via passive diffusion across the luminal and
abluminal cell membranes. To regulate passive transport into
the brain, efflux pumps return many unwanted molecules back
to the circulatory system. Small polar molecules, such as glu-
cose, amino acids, organic anions and cations, and nucleosides,
can cross the blood-brain barrier by carrier-mediated transport.
These solute carriers may be specific to one molecule or multi-
specific to several molecules. Large solutes, such as proteins and
peptides, are transported across the BBB by receptor-mediated
or adsorption-mediated endocytic transport. Highlighting the
important role of transport, it has been estimated that 10–15% of
all proteins in the neurovascular unit are transporters (Enerson
and Drewes, 2006). As a result of this regulated transport, there
can be large differences in the concentration of amino acids
and proteins while differences the concentration of ions in the
blood and cerebral spinal fluid are relatively small (Abbott et al.,
2006).
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FIGURE 3 | Transport systems at the blood-brain barrier. (1) Small ions
and water molecules can cross the blood-brain barrier through ion channels.
(2) Small lipophilic molecules that are soluble in the hydrophobic core of the
cell membrane can be transported passively across the cell. (3) Essential
polar molecules that cannot diffuse through the cell membrane are shuttled
across the cell membranes by carrier-mediated transport. These solute
carriers may be directional, in or out of the cell, or bidirectional. Other
molecules can be actively transported across endothelial cell membranes by
carrier-mediated transporters, receptor-mediated transporters,
adsorption-mediated transcytosis, or efflux pumps.
Passive transport is a way to bypass the array of substrate spe-
cific transport systems that are designed to regulate transport
across the blood-brain barrier. In general, passive transcellular
transport is limited to small molecules that have a combination
of sufficient hydrophilicity to be soluble in water and sufficient
lipophilicity to be soluble in the hydrophobic core of the lipid
bilayer. Small gaseous molecules such as O2 and CO2 can dif-
fuse through the cell membrane, as well as small molecules such
as barbiturates, ethanol, and caffeine. Almost no large molecules
and 98% of all small molecules do not cross the BBB.(Pardridge,
1998, 2010) In general, molecules that passively diffuse across the
BBB have a MW < 500 Da, log Poct in the range 2–4, and the
number of hydrogen bond donors is less than 5 (Avdeef, 2001;
Lipinski et al., 2001). Many molecules that cross the membrane
by passive transport are subsequently transported back to the
vascular system by efflux pumps.
The details of transport from a capillary into the brain remain
poorly understood. As described above, BMECs are surrounded
by pericytes that extend processes over the capillary surface, a
50–100 nm thick basement membrane, and astrocyte end-feet
that almost completely surround the outside of the capillaries.
Transport across an endothelial cell in a capillary may not be
radially symmetric since the cell thickness, and hence diffusion
length, is dependent on position. From transmission electron
microscope images of rat brain capillaries, the endothelial cell
thickness ranges from about 0.2μm away from the nucleus to
about 0.9μm in the vicinity of the nucleus (Farkas and Luiten,
2001; Nicaise et al., 2009). Once transported across the endothe-
lium, a molecule enters the basement membrane where it can be
transported into a pericyte or astrocyte, or can diffuse laterally to
a gap between astrocyte end-feet and into the extracellular space.
To predict the spatial and temporal distribution of a molecule in
the brain will require detailed characterization of the transport
properties of the cellular andmatrix components of the neurovas-
cular unit, along with an understanding of how these properties
change with time, for example during development, aging, and
disease.
LIPOPHILICITY
Lipophilicity is the affinity of a molecule for a lipophilic environ-
ment (McNaught andWilkinson, 1997). The partition coefficient
P is the ratio of the concentration of the molecule in a solvent
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such as octanol to the concentration in water (Poct; Avdeef,
2001; Waterhouse, 2003). The solvent is selected to mimic the
hydrophobic environment of the core of a lipid bilayer. Explicitly,
P is defined for all neutral species and is pH independent. If the
molecule can be ionized then the lipophilicity is determined by
the distribution coefficient D which takes into account ionized
species. Depending on the pKa, the distribution coefficient will
show a pH-independent regime where the molecule is neutral
and a pH dependent regime where the molecule is ionized. In
general, ionization results in increased solubility but decreased
partitioning to octanol.
The lipid composition of the membrane of human BMECs
is ∼33% phosphatidyl choline (PC), 25% phosphatidyl
ethanolamine (PE), 17% sphyngomyelin (Sph), 11% phos-
phatidyl serine (PS), 4.8% phosphatidyl inositol (PI; Siakotos
et al., 1969; Tewes and Galla, 2001).
IN VITRO MEASUREMENTS
The transwell assay
The development of an in vitro platform to study transport across
the blood-brain barrier has proven challenging. This is not sur-
prising, as brain capillary endothelial cells transduce signals from
surrounding astrocytes, pericytes, and from the vascular system.
In vitro transport measurements are usually performed using a
transwell assay where a confluent monolayer of endothelial cells is
formed on a porous support separating two chambers (Figure 4).
The permeability can be determined from the transport of a drug
or fluorescent probe from the donor side to the acceptor side.
Alternatively, ion transport can be characterized in terms of the
electrical impedance of the monolayer.
The transwell assay is widely used to study absorption of
orally administered molecules in the intestine (Artursson, 1991;
Artursson et al., 2001; Stenberg et al., 2001; Hubatsch et al., 2007).
Caco-2 cells of passage 30–45 are plated on polymer membranes
with 1μm pores and cultured for 20–23 days to confluence.
Confluence is confirmed by a resistance measurement of over 200
cm2. After confluence is reached, permeability measurements
can be made across the monolayer. A permeability of > 10−6 cm
s−1 is correlated with 100% oral absorption, whereas a permeabil-
ity of < 10−7 cm s−1 is correlated with less than 1% oral absorp-
tion. Permeabilities for common drugs include 5.3× 10−5 cm
FIGURE 4 | Schematic illustration of (a) in vitro and (b) in vivo
transport measurements. (A) In the 2D transwell assay, a monolayer of
cells is formed on a porous membrane separating two compartments.
Astrocytes and/or pericytes may be seed on the opposite side of the
membrane or in the output chamber. (B) In vivo studies, a solute is injected
into the blood of an animal model, and the penetration into the brain
measured using a suitable chemical detection assay or imaging technique.
s−1 for ibuprofen, 2.0 × 10−6 cm s−1 for benzyl penicillins, and
1.6× 10−7 cm s−1 for doxorubicin (Yee, 1997). Caco-2 cells are
also widely used for determining whether a substance is a P-gp
substrate by measuring the bidirectional permeability (Balimane
et al., 2006).
2D models of the blood-brain barrier for transport studies
historically utilize monolayers of type II Madin-Darby canine
kidney (MDR1-MDCK) cells, genetically engineered to express
the Pg-p pump. Other cell types used for the transwell assay
are primary BMECs isolated from human or animal brain tis-
sue. These cells are usually plated on transwell membranes coated
with rat tail collagen I or basement membrane proteins such as
collagen IV, fibronectin, laminin (Tilling et al., 1998). BMECs
are often co-cultured with astrocytes and/or pericytes to induce
blood-brain barrier properties. Astrocytes are commonly cul-
tured in the lower compartment of the transwell dish, either
on the opposite side of the membrane from the endothelial
cells or on the bottom of the dish to provide secreted fac-
tors (Siddharthan et al., 2007). Astrocyte-conditioned media is
also commonly used in transwell systems, as the soluble fac-
tors secreted by astrocytes, such as bFGF and GDNF, have been
shown to increase tight junction properties (Abbott et al., 2006).
The influence of pericytes on transport in the transwell assay
is not well-understood and may be dependent on their stage
of differentiation (Thanabalasundaram et al., 2011). Tri-culture
models with endothelial cells plated on a transwell membrane,
either astrocytes or pericytes on the opposite side of the mem-
brane, and the third cell type plated on the bottom of the dish
have been found to improve blood-brain barrier properties com-
pared to co-culture (Nakagawa et al., 2009; Hatherell et al.,
2011).
Transendothelial electrical resistance (TEER)
The first in vivo transendothelial electrical resistance measure-
ments were performed on frog brain microvessels in a two-
electrode configuration with one electrode inserted into the vessel
and the other used to measure the voltage drop as a function of
distance along the vessel (Crone and Olesen, 1982). The voltage
drop along a cylindrical vessel can be related to the TEER:






where V(x) is the voltage at distance x, and λ is the characteristic
length which depends on the vessel radius and the resistivity of
blood. The transendothelial resistance Rm of the endothelial cells
defining the lumen of the vessel is then determined from:
Rm = 2πaRiλ (2)
where Ri is the internal resistance of the capillary ( cm−1) and a




where ρi is the resistivity of blood (cm). Blood resistivity is
exponentially dependent on the hematocrit, with a typical value
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of around 120cm corresponding to a 40% hematocrit. Blood
plasma has a resistivity of around 50cm (see Supplementary
Information). Note that the resistance is normalized to unit area
of the endothelium and has units of cm2.
From these experiments the average resistance was determined
to be 1840cm2 (Crone and Olesen, 1982). Subsequent experi-
ments with rat brain surface microvessels determined the average
resistance of venous microvessels to be 800 cm2, and the aver-
age resistance of arterial microvessels to be 2000cm2, with an
overall average of 1500cm2 (Butt and Jones, 1992). TEER mea-
surements have been widely used to characterize tight junctions
(Madara, 1998; Franke et al., 1999; Gumbleton and Audus, 2001;
Reichel et al., 2003; Deli et al., 2005; Shen et al., 2011).
TEER measurements using the transwell assay generally
result in resistances much lower than the values of 1500–2000
cm2 reported for in vivo measurements. Values in excess
of 150–200cm2 are generally considered suitable for study-
ing solute and drug transport (Reichel et al., 2003). There
are two contributing factors to this difference. First, the tran-
swell assay does not recapitulate all of the physical and bio-
logical features of the BBB, resulting in the formation of
cell-cell junctions that are not quite as effective in restrict-
ing paracellular transport. Second, there is usually a short cir-
cuit path due to incomplete monolayer formation or poor
adhesion to the walls of the transwell support. In the tran-
swell assay, if we consider a short circuit resistance in parallel
with the endothelial resistance then the measured resistance is
given by:





where Rs is the solution resistance, Rsc is the short circuit resis-
tance, Rm is the endothelial cell resistance, and fc is the fraction
of the transwell surface covered with a confluent monolayer of
endothelial cells. Note that when fc → 1, Rmeas ≈ Rm as long
as Rm  Rs. Taking Rs = 2cm2, Rsc = 5cm2, and Rm =
1500cm2, the typical range of resistances for in vitro mea-
surements correspond to a coverage fraction from 0.90 to 0.98.
The problem associated with a short circuit path at the perime-
ter of the TEER device can be overcome by plating cells on
microfabricated electrodes. The disadvantage of using microfab-
ricated electrodes is that there is no solution reservoir underneath
the cell monolayer making it very difficult to perform transport
measurements.
While the relatively low TEER values usually obtained in
transwell experiments (150–200cm2) makes it difficult to
compare experiments quantitatively to in vivo conditions, it
still allows qualitative assessment of conditions that induce
BBB properties. For example, the important role of astro-
cytes in inducing BBB properties is demonstrated by the
increase in TEER values observed by co-culture of BCECs
with astrocytes or astrocyte-conditioned media (debault and
Cancilla, 1980; Abbott, 2002). Similarly, the increase in
TEER observed in tri-culture models provides additional evi-
dence for the role of pericytes in the induction of BBB
properties.
PERMEABILITY
The rate of transport of a solute across a barrier is characterized
by the permeability, which is defined as the flux through unit area
under unit concentration gradient and has units of cm s−1. It is
implicitly assumed that there is no hydrostatic or osmotic pres-
sure difference across the barrier (Kedem and Katchalsky, 1958).
In the analysis of transport across the blood-brain barrier, the
endothelium is generally considered a black box with first order
rate constants kin and kout where kin describes transport of a
solute into the brain and kout describes the reverse process (see
Figure 5).




= kincin − koutcout (5)
where N is the number of moles transported across the volume
element, cin is the concentration (mol cm−3) on the input side
FIGURE 5 | Schematic illustration of analysis of diffusion transport in
2D and 3D. In 2D: cin is the solute concentration on the input side in a
transwell assay, A is the area of the cell monolayer (cm2), N is the number
of moles of solute measured on the output side in volume V (cm3), and
kin, 2D is the 2D rate constant (cm3 s−1). As long as cin = constant then
kin, 2D = P2DA. In 3D: cpl is the solute concentration in plasma (gs cm−3), S
is the normalized surface area of the lumen (cm2 gbr−1), and F is the
normalized flow rate (cm3 gbr−1 s−1), Qbr is the amount of solute
transported to the brain (gs gbr−1), and kin, 3D is the 3D rate constant
(cm s−1 gbr−1).
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FIGURE 6 | Kinetics of solute transport across a 2D monolayer. cout/cin
is plotted as a function of time t, with A = 1 cm2, and V = 1 cm3 for ( )
P2D = 10−5 cm s−1, and ( ) 10−6 cm s−1, and (•) P2D = 10−7 cm s−1, At
short times (inset) where P2DAt/V  1, the slope is P2DA/V and the rate
constant can be obtained from kin,2D = P2DA.
and cout is the concentration on the output side. In all experi-
ments it is implicitly assumed that paracellular transport across
the tight junctions is negligible. For the case where transport is
dominated by passive diffusion across the cell membranes then
kin = kout assuming negligible difference in lipid composition
between the luminal and abluminal membranes. However, if a
solute is a substrate for a transporter, such as an efflux pump then
kin 	= kout.
The flux may be normalized in different ways, depending on
the type of experiment. For example, the in vitro transwell assay
is a 2D assay where the input and output compartments are sep-
arated by a monolayer of endothelial cells. In contrast, in vivo
brain perfusion is a 3D assay. The difficulties in performing in vivo
transport measurements can make comparison of 2D and 3D
measurements somewhat confusing, for example, the in vitro
(2D) rate constant kin, 2D is normalized to unit area whereas the
in vivo (3D) rate constant kin, 3D is usually normalized to unit
mass.
2D TRANSPORT
In vitro transport studies are typically performed using a 2D tran-
swell assay where a confluent monolayer of endothelial cells on
a porous support is located between input and output cham-
bers (Figure 4) (Siflinger-Birnboim et al., 1987; Karlsson and
Artursson, 1991; Artursson, 1991; Adson et al., 1994; Cecchelli
et al., 1999; Youdim et al., 2003; Deli et al., 2005). A solute, typi-
cally radio-labeled or fluorescently-labeled, is introduced into the
input chamber and the amount accumulated in the output cham-
ber is measured as a function of time, typically over a period of
1–2 h (Bowman et al., 1983; Audus and Borchardt, 1986; Shah
et al., 1989; Karlsson and Artursson, 1991; Artursson, 1991; Freed
et al., 2001; Chappa et al., 2006; Summerfield et al., 2007). The
concentration of solute on the input side cin (mol cm−3) and
the area A (cm2) of the monolayer are the input parameters, and
the concentration of solute on the output side is measured as a
function of time. Note that cout = N/V where N is the number
of moles of solute and V (cm3) is the fluid volume in the output
chamber.
Integrating Fick’s first law and recognizing that kin, 2D = P2DA










(see Figure 6 and Supplementary Information) (Kedem and
Katchalsky, 1958; Siflinger-Birnboim et al., 1987; Dawson, 1991;
Tran et al., 2004)At short times where P2DAt  V, the exponen-
tial term can be linearized and hence:
N(t) = P2DAcint (7)
In the derivation of Equation 7 it is assumed that: (1) the
concentration of solute in the input chamber (cin) is approx-
imately constant, (2) transport from the output chamber to
the input chamber can be neglected (koutcout → 0), and (3)
transport is dominated by passive diffusion across the cell
membrane (see Supplementary Information). Experimentally,
the permeability can be obtained from the slope of a plot
of N(t)/Acin vs. time at short times where P2DAt/V  1.
Alternatively, cout/cin can be plotted against t where the slope
is P2DA/V. The rate constant can then be obtained from
kin, 2D = P2DA.
Experimentally, transport of a solute from the input cham-
ber to the output chamber involves transport across the aqueous
boundary layer above the cell monolayer, transport across the cell
monolayer, and transport through the porous membrane. These










where Pm is the permeability coefficient of the cell monolayer,
Pf is the permeability coefficient of the transwell membrane,
and PS is the permeability of the boundary layer above the cell
monolayer (Barry and Diamond, 1984; Karlsson and Artursson,
1991; Artursson, 1991; Adson et al., 1994; Avdeef et al., 2005).
To ensure that the measured permeability coefficient P2D = Pm
requires that Pm  Pf and PS. The influence of Pf and PS can be
approximated using diffusion models (Karlsson and Artursson,
1991 and Artursson, 1991; Avdeef et al., 2005), or reduced by stir-
ring (decreasing 1/PS; Cecchelli et al., 1999; Youdim et al., 2003;
Summerfield et al., 2007) and using a transwell filter with larger
pores (decreasing 1/Pf ; Siflinger-Birnboim et al., 1987; Adson
et al., 1994). Alternatively, the sum of 1/Pf and 1/PS can be mea-
sured in a control experiment with no cells on the transwell
membrane.
Permeability coefficients obtained using the transwell assay are
typically in the range from 10−7 to 10−3 cm s−1 (Pardridge et al.,
1990; Deli et al., 2005; Summerfield et al., 2006, 2007), some-
what higher than values measured in vivo. Typical P2D values
for marketed CNS drugs vary between 10−7 and 10−5 cm s−1
(Summerfield et al., 2007). The measured permeability coeffi-
cient P2D increases with lipophilicity reaching a plateau around
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logPoct = 3. Increasing the lipophilicity above logPoct = 3 results
in a reduction of P2D (Summerfield et al., 2007).
In general, P2D increases approximately linearly with increas-
ing lipophilicity. Deviations from this trend are generally
due to violation of the assumption that transport is domi-
nated by passive diffusion across the cell membrane. Apparent
increases in P2D can result from active transport and appar-
ent decreases may be due to the influence of efflux pumps.
At higher lipophilicities, solute trapping in the cell membrane
and internal vesicles can lead to a lower apparent solute con-
centration in the output chamber and hence a lower appar-
ent permeability.
RESECTED VESSEL ASSAY
As described above, the in vitro transwell assay is widely used
to study passive transport across BMECs. However, the tran-
swell assay has limited utility in studying active transport, since
it is difficult to recapitulate the physiological polarization of
pumps and transporters. A complementary method that is par-
ticularly useful in studying efflux pumps is the resected vessel
assay (Schramm et al., 1995; Miller, 2003; Hartz et al., 2004;
Bauer et al., 2005; Wang et al., 2010; Campos et al., 2012).
In this assay, a resected brain capillary, typically from a rat or
mouse brain, is transferred to a dish and immersed in buffer.
A fluorescently-labeled solute of interest is then introduced into
the media and uptake is measured by recording the fluorescence
in the lumen of the vessel. The solute is usually a substrate
for a particular transporter. For example, NBD-CSA is a fluo-
rescent derivative of cyclosporine A that is a substrate for the
P-gp pump (Didier et al., 1996), BODIPYFL prazosin is a flu-
orescently labeled substrate for BCRP (Robey et al., 2001), and
Texas red is a fluorescent substrate for MRP2 (Bauer et al.,
2008).
In the resected vessel assay, the solute is introduced into
the bath, corresponding to the brain side of the vessel. The
solute is transported across the abluminal membrane, diffuses
across the cell, and then is transported across the luminal mem-
brane. In general, the solute concentration in the lumen increases
with time and reaches a steady state value after 30–60min.
Common efflux pumps such as P-gp and BCRP1 are expressed
preferentially on the luminal membrane, therefore the concen-
tration of the solute in the lumen of the vessel can be larger
than in the bath. Since the direction of transport is from the
brain parenchyma side to the vessel lumen, inhibition of efflux
pumps is expected to decrease the solute concentration in the
vessel.
Transport across the endothelium of a resected vessel can
be analyzed using the model in Figure 7A (Ye and Searson,
unpublished). Assuming that intracellular transport is fast in
comparison to passive transport across the membrane that the
forward and backward rate constants for passive diffusion are
the same (km = k−m), and that the solute concentration inside
the cell is approximately constant, we obtain (see Supplementary
Information):











FIGURE 7 | (A) Schematic illustration of a resected brain capillary defined
by a layer of endothelial cells immersed in a bath. km is the rate constant
for passive diffusion across a cell membrane. It is implicitly assumed that
passive diffusion across the apical and luminal membranes is the same.
kpgp is the rate constant for active transport via efflux pumps from the cell
to the lumen. It is assumed that active transport at the apical membrane is
negligible. kin and kout represent the overall rate constants for transport
from bath to lumen and lumen to bath, respectively. (B) Accumulation of
solute in the lumen for a resected capillary with diameter d = 5μm,
P3D = 3× 10−7 cm s−1, kpgp/km = 0, 5, 10,20.








Figure 7B shows plots of clum(t)/cbath vs. time for different values
of kpgp/km for a vessel obtained from Equation 9. The concen-
tration increases exponentially with time up to a steady-state
value that is dependent on the ratio of kpgp/km. Note that with-
out the P-gp transporter (i.e., kpgp = 0), clum(∞)/cbath = 1 and
kin = kout = km/2. As long as kpgp/km > 0 then clum(∞)/cbath >
1. The time to reach a steady state solute concentration in the
lumen increases with increasing kpgp/km. Results from experi-
ments reported in the literature show a time to reach steady state
of 30–60min (Hartz et al., 2004; Bauer et al., 2007; Hawkins et al.,
2010; Cannon et al., 2012), consistent with kpgp/km ≈ 5.
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From examination of the model it can be seen that rate con-
stant km = 2P0, where P0 is the permeability for passive diffusion
across the cell. P0 can be equated to values obtained from in vitro
transwell experiments or in vivo perfusion experiments where
transport is dominated by passive diffusion. Typical values for P0
range from 10−8 to 10−4 cm s−1 (Summerfield et al., 2007).
3D TRANSPORT
Various in vivo techniques, such as intravenous injection, in situ
brain perfusion, microdialysis, and positron emission tomogra-
phy (PET), have been employed to determine the kinetics of drug
transport across the BBB (Takasato et al., 1984; Ungerstedt, 1991;
Pike, 2009; Kuhnline Sloan et al., 2012). Brain perfusion in rats is
the most widely used technique for obtaining in vivo permeability
values for small molecules and drugs (Hammarlund-Udenaes
et al., 2009). Brain perfusion allows injection of a solute into
the brain vasculature at higher flow rates and solute concen-
trations than can be achieved through systemic circulation
and hence allows a wider range of solute permeabilities to be
measured at a fixed perfusate concentration (Takasato et al.,
1984; Hammarlund-Udenaes et al., 2009). Direct injection of
the solute into the brain minimizes metabolic loss and plasma
protein binding (Takasato et al., 1984). In this technique, the
main blood supply leading to an animal’s brain, often the
common carotid artery (either left or right), is cannulated and
connected to a perfusion system. Immediately after the animal’s
heart is stopped, a molecule of interest dissolved in physiological
perfusate solution is infused into its brain typically for 5–300 s.
Subsequently, the brain is removed and the ipsilateral hemisphere
is dissected, weighed, and the solute concentration determined
by LC-MS, HPLC, GC, or scintillation counting if the solute is
radiolabeled (Smith, 2003).
The rate constant for in vivo transport (kin, 3D) can be obtained
from the measured solute concentration in the brain Qbr (gs
gbr−1; see Figure 5):
Qbr = kin, 3Dcp1t (11)
where cpl is the solute concentration in plasma (gs cm−3). In the
derivation of Equation 11 it is assumed that: (1) the concentra-
tion of solute in plasma (cpl) is constant and (2) the flux of solute
out of the brain is not significant over the short infusion period
(i.e., kout, 3Dcbr ≈ 0), which implies unidirectional transport (see
Supplemental Information).
The rate constant, kin, 3D, is obtained from a single mea-
surement of Qbr/cpl at a fixed infusion time t. The assump-
tion of unidirectional transport can be confirmed by per-
forming multiple perfusion experiments as a function of
infusion time and determining the slope (kin, 3D) of a lin-
ear regression to a plot of Qbr/cpl vs. time (Pathak et al.,
2011).
While kin, 3D can be used to compare the in vivo trans-
port kinetics of different solutes (Youdim et al., 2003), it can-
not be compared directly to in vitro measurements kin, 2D. The
rate constant kin, 3D is related to the permeability P3D through
the Crone–Renkin equation (see Supplemental Information)
(Renkin, 1959; Crone, 1963):








where F is the normalized flow rate (cm3 s−1 gbr−1) and S is
the normalized luminal surface area of vessels (cm2 gbr−1) in the
brain. For the case where the flow rate F  P3DS, which is equiv-
alent to the initial assumption that the plasma concentration of
the solute cpl is constant, the exponential term can be linearized
and hence:
kin, 3D = P3DS (13)
Experimentally, as long as F ≥ 5P3DS, then the error in measure-
ment of P3D using Equation 13 is ≤ 10% (Smith and Takasato,
1986; Smith and Allen, 2003). S is taken to be 100–240 cm2
gbr−1, as determined by morphometric analysis of rat brain tissue
sections (Gross et al., 1986; Fenstermacher et al., 1988).
Typical values of P3D for vascular tracers, nutrients, and
drug molecules vary over 4 orders of magnitude from 10−8 to
10−4 cm s−1 (Takasato et al., 1984; Liu et al., 2004; Youdim
et al., 2004; Summerfield et al., 2007). For small hydrophilic
molecules, such as mannitol and sucrose, P3D is typically in the
range 10−8 − 10−7 cm s−1. In contrast, top selling antipsychotics
and antidepressants such as venlafaxine, risperidone, buproprion,
are generally small lipophilic molecules with P3D values between
10−5 and 10−4 cm s−1 (Summerfield et al., 2007). Caffeine
has an intermediate lipophilicity (logPoct = −0.08) but relatively
high permeability (P3D = 4.2× 10−5 cm s−1; Liu et al., 2004).
Similarly, ethanol has an intermediate lipophilicity (logPoct =
−0.3) but a high permeability (P3D = 1.1 × 10−4 cm s−1; Ohno
et al., 1978; Takasato et al., 1984; Gratton et al., 1997).
The in vivo 3D permeability for many small molecules
increases linearly with lipophilicity up to logPoct ≈ 3, implying
that transport from the blood to the brain is dominated by passive
transport across the cell membranes (see Figure 8A) (Ohno et al.,
1978; Rapoport et al., 1979; Smith and Takasato, 1986; Lipinski
et al., 2001; Liu et al., 2004; Summerfield et al., 2007; Zhao et al.,
2009). Deviations from this behavior are indicative of other trans-
port mechanisms (Lipinski et al., 2001). For example, D-glucose
has a very low lipid solubility (logPoct ≈ −3), but exhibits a high
permeability coefficient (P3D ≈ 10−5 cm s−1) since transport is
facilitated by the GLUT-1 transporter. Conversely, colchicine has
relatively high lipid solubility (logPoct ≈ 2) but has a low per-
meability coefficient (P3D ≈ 10−6 cm s−1), since it is a substrate
of the P-gp efflux pump (Youdim et al., 2003; Liu et al., 2004).
Morphine has a relatively low permeability (P3D = 1.1× 10−6
cm s−1) by drug standards, in part because it is a substrate for
the P-gp pump (King et al., 2001), but highlights the fact that rel-
evant doses can be achieved over reasonable time scales (Bouw
et al., 2000; Tunblad et al., 2003; Hammarlund-Udenaes et al.,
2008). Codeine (methyl morphine) has an -OH group on mor-
phine substituted by a -O-CH3 group, resulting in an increase
in logPoct from 0.2 to 1.24, and increased permeability (Bostrom
et al., 2008; Hammarlund-Udenaes et al., 2008). Dopamine has an
intermediate lipophilicity (logPoct = 0.84) but low permeability
(P3D = 1.1 × 10−6 cm s−1). However, L-dopa, a precursor that is
metabolized to dopamine in the brain, has a very low lipophilicity
(logPoct = −2.53) but high permeability (P3D = 6.6 × 10−6 cm
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s−1) since it is a substrate for the LAT-1 transporter (Gratton
et al., 1997).
For logPoct ≥ 3, both the apparent in vitro and in vivo perme-
abilities reach a maximum at about 10−4 cm s−1 (see Figure 8B)
(Lipinski et al., 2001; Summerfield et al., 2007; Zhao et al., 2009).
There are several factors that contribute to this apparent maxi-
mum. For solutes with high lipophilicity, transport becomes flow-
limited. For in situ brain perfusion, the plasma concentration of
the solute cpl remains constant as long as F  P3DS (or P3D 
F/S). Since the maximum flow rate is typically around 0.2 cm3
s−1 gbr−1, and assuming a luminal surface area of 100–200 cm2
gbr−1, the plasma concentration cpl is expected to remain constant
for values of permeability up to P3D ≈ 10−4 cm s−1. At this limit
and above, most of the injected solute is absorbed into the brain,
and as a result, the in vivo permeability does not increase with
lipophilicity for logPoct > 3. For in vitro measurements, at high
FIGURE 8 | (A) Permeability of tracers, nutrients, and drugs obtained from
in situ rat brain perfusion vs. lipophilicity. (•) Summerfield et al. (2007), ()
Takasato et al. (1984), () Youdim et al. (2004), ( ) Liu et al. (2004) (B)
Comparison of permeability of various CNS drugs obtained from transwell
assays on monolayers of MDR1-MDCK (P2D) and in situ rat brain perfusions
(P3D). P3D values were obtained from in situ rat brain perfusion
measurements reported in the literature. For data reported as the
permeability surface area products (P3DS, cm3 s−1 gbr−1) we take
S = 150 cm2 gbr−1. Values of P3D where S 	= 150 cm2 gbr−1 were
recalculated with S = 150 cm2 gbr−1. Corresponding literature values for
logPoct were obtained from calculation Liu et al. (2004), Summerfield et al.
(2007), and Youdim et al. (2004) or direct measurement of solute
partitioning into octanol and water phases [Takasato et al. (1984)].
rates of uptake, the apparent permeability can become limited
by transport across the boundary layer or the porous mem-
brane, as described above, resulting in an apparent maximum in
permeability.
A noticeable difference between P2D and P3D occurs at
logPoct > 3. While P3D maintains a plateau in this regime, P2D
decreases with increasing logPoct for both MDCK and Caco-
2 models (Wils et al., 1994; Sawada et al., 1999; Summerfield
et al., 2007). This effect can be explained by solute binding
and absorption in the cell membrane (Kubinyi, 1977). As a
result, fewer molecules are able to efflux from the endothe-
lium into the output chamber, thus contributing to a decrease
in the apparent permeability (P2D). In the transwell assay, the
amount of solute bound to the cell membrane, termed mem-
brane retention or association, can be substantial (Sawada et al.,
1999; Avdeef, 2001, 2003; Youdim et al., 2003; Fujikawa et al.,
2007).
For in vivo transport, solute binding or trapping can be more
complicated (Figure 9). Solute that is transported across the brain
endothelium can diffuse through the interstitial fluid in the ECM,
as described previously, and ultimately be taken up by neurons or
glial cells in the brain. However, solute in the interstitial fluid can
also bind to the ECM and hence be unavailable therapeutically.
Characterization of in vivo transport therefore requires knowl-
edge about additional parameters. In one approach, the dynamics
of solute transport in vivo can be captured by three parameters:
Kp,u, P3D, and Vu,brain (Hammarlund-Udenaes et al., 2008). Kp,u
is the ratio of unbound drug in the brain and blood at steady
state, and typically has values between 0.02–3. Kp,u = 1 for pas-
sive transport, Kp,u < 1 for active efflux, and Kp,u > 1 for active
influx. P3D describes the permeability of transport into the brain
and can vary by four orders of magnitude (Figure 8). For passive
transport, P3D is expected to be related to the lipophilicity. The
product P3DS (cm3 s−1 gbr−1) corresponds to the net influx or
clearance into the brain. Vu,brain (mL gbr−1) is a measure of the
FIGURE 9 | Schematic illustration of solute transport from the vascular
system into the brain. The solute may bind with proteins or other
components in blood that may reduce the amount that can enter the brain.
Solute transported across the endothelium may be partitioned between the
interstitial fluid and intracellular fluid in neurons and glial cells. Solute in the
interstitial fluid may be bound to the ECM, reducing the amount available
for uptake by cells.
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distribution of the solute in the brain and is given by the ratio
of the total amount of solute in the brain (mol gbr−1) to the
unbound concentration in the interstitial fluid (mol mL−1). If
all of the solute is in the interstitial fluid and there is no solute
in the brain cells, then Vu,brain = 0.2mL gbr−1, corresponding to
the volume of interstitial fluid per gram in the rat brain. If the
solute is uniformly distributed between the interstitial fluid and
the intracellular fluid then Vu,brain = 0.8mL gbr−1, correspond-
ing to the volume of water per gram in the rat brain. Values of
Vu,brain > 0.8mL gbr−1, correspond to the case where the solute
has affinity for brain tissue.
THE BLOOD-BRAIN BARRIER AND DISEASE
The barrier function of the BBB is critical for regulating trans-
port to the brain, but also represents a significant roadblock in
delivering drugs to the brain. Central nervous system diseases
include mental disorders, migraine, epilepsy, neurodegenerative
disease (e.g., Alzheimer’s, Parkinson’s, ALS, Huntington’s), cere-
brovascular disease (e.g., stroke), cancer, inflammatory disease
(e.g., MS), trauma, and infections (e.g., meningitis; Hawkins and
Davis, 2005; Hirtz et al., 2007; Neuwelt et al., 2008, 2011; Abbott
et al., 2010; Daneman, 2012). Only very few CNS disorders such
as depression, schizophrenia, chronic pain, and epilepsy are cur-
rently treatable with small molecule drug therapy. The BBB is
the major roadblock in developing therapies for neurodegen-
erative diseases, cerebrovascular disease, inflammatory disease,
infections, trauma, and brain cancer (de Boer and Gaillard, 2007;
Pardridge, 2010).
Since the BBB is critical to maintain homeostasis in the brain,
disruption can lead to changes in permeability, modulation of
immune cell transport, and trafficking of pathogens into the
brain (Hawkins and Davis, 2005; Engelhardt, 2008a,b; Abbott
et al., 2010; Neuwelt et al., 2011). Disruption of the BBB is
associated with many diseases of the central nervous system,
including neurodegenerative diseases [e.g., Alzheimer’s disease
(Kalaria, 1999; Zlokovic, 2005; Desai et al., 2007; Zipser et al.,
2007; Meyer et al., 2008; Hartz et al., 2010), ALS (Zhong et al.,
2008), and Parkinson’s disease (Kortekaas et al., 2005; Desai et al.,
2007; Bartels et al., 2008)], cerebrovascular diseases [e.g., stroke
(Belayev et al., 1996; Lippoldt et al., 2000; Lo et al., 2003; Del
Zoppo, 2010; Moskowitz et al., 2010)], epilepsy and seizures
(Seiffert et al., 2004; Oby and Janigro, 2006; Remy and Beck,
2006), brain infections [e.g., HIV encephalitis (Dallasta et al.,
1999; Berger and Avison, 2004; Persidsky et al., 2006; Ivey et al.,
2009) and meningitis (Uchiyama et al., 2009)], inflammatory dis-
eases [e.g., MS (Kermode et al., 1990; Minagar and Alexander,
2003; Gold et al., 2006; Waubant, 2006; McQuaid et al., 2009)],
brain tumors (Davies, 2002; Papadopoulos et al., 2004; Bronger
et al., 2005), and neurotrauma (Stahel et al., 2000; Kim and
Dustin, 2006; Shlosberg et al., 2010). There is also emerging
evidence that mental or psychological stress may lead to local
disruption of the BBB (Friedman et al., 1996). The association
of BBB disruption with CNS diseases, suggests that BBB repair
may prove to be an effective approach to maintain health and aid
recovery from disease, infection, or injury (Abbott et al., 2010).
FUTURE PERSPECTIVES
Drug delivery to the brain remains a major obstacle for treatment
of CNS disorders. Advances in our understanding of the structure
and function of the blood-brain barrier and development of inno-
vative approaches for circumventing this barrier will be required
to overcome the restricted access to brain circuits (Neuwelt et al.,
2011). Moreover, there is an increasing appreciation that blood-
brain barrier disruption contributes to the progression of central
nervous system diseases. A key challenge is in understanding the
dynamic response of barrier elements to focal disruptions and in
developing strategies to accelerate repair.
While there is emerging insight into the formation of the
blood-brain barrier during development (Daneman et al., 2010;
Sohet and Daneman, 2013), very little is known about how aging
affects barrier function. This is important, as the greatest risk fac-
tor for neurodegenerative disorders is aging. Insight into the mor-
phology, turnover, dynamic behavior, and mechanical properties
of endothelial cells during aging, as well as functional interactions
with other cell types in the neurovascular unit will be required to
define the role of BBB changes in both age-dependent cognitive
decline and the progression of neurodegenerative diseases.
Central to advances in our scientific understanding of the BBB
will be improved models for scientific and translational research.
From an engineering perspective, the key features of the neu-
rovascular unit are: (1) BMECs that function in a cylindrical
geometry and experience shear stress resulting from blood flow,
(2) functional interactions between BMECs, astrocytes, pericytes,
other glial cells and neurons, (3) blood, which contains multi-
ple cell types and soluble factors, and (4) 3D extracellular matrix
and basement membrane. Determining how these features of the
microvasculature interact will aid in the generation of BBB mod-
els compatible with high throughput screening methods that are
likely to be crucial to the development of novel therapeutics.
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